Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER

Trial Title: Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER

NCT ID: NCT06528743

Condition: Patients With NSCLC Stage 2-4

Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Sequential Assignment

Intervention model description: Initially, patients are included following a 3+3 design to find the maximum tolerated break length, followed by an expansion cohort (unless there are already 2+ patients drop out in schedule 1, then there will be no expansion cohort).

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
Description: Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
Arm group label: Primer shot treatment break of 1 week
Arm group label: Primer shot treatment break of 2 weeks
Arm group label: Primer shot treatment break of 3 weeks

Summary: Intro/rationale: Radiotherapy employs uniform, equally spaced weekday fractions that do not account for changes in tumor radiosensitivity. However, radiobiological characteristics evolve during the radiotherapy schedule as reoxygenation increases radiosensitivity. In tumor-response simulations and preclinical experiments, it was superior to prime the tumor with one radiotherapy fraction, followed by a treatment break permitting mitotic cell death and reoxygenation of tumor cells. Objective: To determine the safety and feasibility of primer shot fractionation for NSCLC. Study design: A prospective non-randomized feasibility trial to test the safety of primer shot fractionation in a 3+3 phase with increasing treatment breaks, followed by an expansion cohort. Study population: Patients with NSCLC stage 2-4, referred for palliative radiotherapy of the primary tumor and possibly (lymph node) metastases. Patients are allowed to receive systemic treatments, except for VEGFR-inhibitors. The 3+3 phase is followed by an expansion phase of 22 patients. Intervention: All treatments are 5x6 Gy to all targets. Patients receive an increasing primer shot treatment break. In the 3+3 phase, the break between the first and the second radiotherapy fraction is: 1, 2 and 3 weeks. The maximum tolerated break length will be used for the expansion cohort. Main study parameters/endpoints: The main study endpoint is the ability of patients to finish the radiotherapy schedule as planned. Secondary endpoints are tumor response at the end of treatment and 3 months thereafter, and acute toxicity. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Based on simulations and preclinical data, primer shot treatment breaks increase tumor control. However, the increased overall treatment time could potentially increase the chance a patient drops out before the radiotherapy schedule is finished. Because of the gradually prolonged break, this risk is relatively small and acceptable for this population. Additionally, patients are asked to fill in PRO-CTCAE lung subset questionnaires at the start of treatment and during follow-up. They will also receive 1 additional CT with contrast at fraction 5.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Age ≥ 18 years - NSCLC (either pathology proven or sufficient clinical suspicion to be treated as NSCLC), referred for palliative radiotherapy of at least the primary tumor site. - Stage 2-4 - WHO performance score 0-2. - Provision of signed, written and dated IC prior to any study specific procedures. Exclusion Criteria: - Interstitial lung disease - Treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors - Prior thoracic radiotherapy (>20 Gy EQD2 a/b 3) overlapping with the current planning target volume

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: August 1, 2024

Completion date: August 1, 2029

Lead sponsor:
Agency: The Netherlands Cancer Institute
Agency class: Other

Source: The Netherlands Cancer Institute

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06528743